United Therapeutics (UTHR) Change in Accured Expenses (2009 - 2026)

United Therapeutics has reported Change in Accured Expenses for 18 years, with the latest figure at -$12.7 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 388.46% year-over-year to -$12.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87.8 million (up 129.84% YoY) and the FY2025 annual result came in at $97.9 million, up 129.27% from the prior year.
• Change in Accured Expenses eased to -$12.7 million in Q1 2026 per UTHR's latest filing, from $23.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $46.1 million in Q2 2025 and troughed at -$23.1 million in Q4 2023.
• A 5-year average of $13.5 million and a median of $22.3 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses surged 228.89% in 2025, then sank 388.46% in 2026.
• Over 5 years, Change in Accured Expenses stood at $9.1 million in 2022, then sank by 353.85% to -$23.1 million in 2023, then rose by 22.08% to -$18.0 million in 2024, then soared by 228.89% to $23.2 million in 2025, then slumped by 154.74% to -$12.7 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$12.7 million, $23.2 million, and $31.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.